10x Genomics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by 10x Genomics, Inc. on January 11, 2026. The filing announces preliminary, unaudited select financial results for the fourth quarter and the full fiscal year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the attached press release (Exhibit 99.1), which is referenced but not included in the provided text.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. Investors must refer to the attached press release for comparative financial data.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The report explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for actual Q4 and full-year 2025 financial figures.
- Verify the unaudited nature of the reported results.
- Check for any forward-looking statements or guidance included in the press release but omitted from this 8-K summary.
- Confirm the filing date of January 11, 2026, and the signature date of January 12, 2026, by General Counsel Randy Wu.